Lymphoplasmacytic lymphoma

Lymphoplasmacytic lymphoma gets its name because the lymphoma cells have characteristics of both lymphocytes and plasma cells. It is an uncommon type of B-cell non-Hodgkin lymphoma (NHL).

Lymphoplasmacytic lymphoma usually occurs in older adults. The average age at diagnosis is 60. It is usually slow growing (indolent). But it can sometimes change into a fast-growing (aggressive) type of NHL.


With lymphoplasmacytic lymphoma, the lymphoma cells are usually found in the bone marrow, lymph nodes and spleen. People with lymphoplasmacytic lymphoma tend to bleed easily. They also have fatigue and weakness. Most people with lymphoplasmacytic lymphoma do not have B symptoms (unexplained fever, drenching night sweats and unexplained weight loss).

The lymphoma cells make varying amounts of a protein called immunoglobulin M (IgM, or macroglobulin). Higher than normal amounts of this protein in the blood can make it thick (called hyperviscosity syndrome). When this occurs, the condition is called Waldenstrom macroglobulinemia. This can lead to problems with circulation and less blood flow to the brain, the eyes or other organs, which can cause:

  • dizziness
  • headache
  • blurred vision or loss of vision
  • shortness of breath
  • numbness and tingling of the fingers or toes (called peripheral neuropathy)
  • muscle weakness
  • confusion


You may be offered one or more of the following treatments for lymphoplasmacytic lymphoma.

Watchful waiting

Watchful waiting (also called active surveillance) may be offered for lymphoplasmacytic lymphoma because it develops slowly and may not need to be treated right away. The healthcare team will carefully monitor the person with lymphoplasmacytic lymphoma and start treatment when symptoms appear, such as hyperviscosity syndrome, or there are signs that the disease is progressing more quickly.


People with lymphoplasmacytic lymphoma who have symptoms or hyperviscosity syndrome are usually given chemotherapy. Chemotherapy drugs that may be used with or without prednisone include:

  • chlorambucil (Leukeran)
  • fludarabine (Fludara)
  • bendamustine (Treanda)
  • cyclophosphamide (Cytoxan, Procytox)

Combinations of chemotherapy drugs that may be used include:

  • DRC – dexamethasone (Decadron, Dexasone), rituximab (Rituxan) and cyclophosphamide
  • BRD – bortezomib (Velcade) and rituximab, with or without dexamethasone
  • CVP – cyclophosphamide, vincristine (Oncovin) and prednisone
  • R-CVP – CVP with rituximab
  • thalidomide (Thalomid) and rituximab

Targeted therapy

Targeted therapy uses drugs to target specific molecules (such as proteins) on the surface of cancer cells. These molecules help send signals that tell cells to grow or divide. By targeting these molecules, the drugs stop the growth and spread of cancer cells while limiting harm to normal cells.

Targeted therapy drugs used alone or in combination to treat lymphoplasmacytic lymphoma include rituximab, bortezomib and ibrutinib (Imbruvica).


Immunotherapy works by stimulating, boosting, restoring or acting like the body’s immune system to create a response against cancer cells. Immunomodulatory drugs are a type of immunotherapy that interferes with the growth and division of cancer cells.

Thalidomide is a type of immunomodulatory drug that may be used to treat lymphoplasmacytic lymphoma.

Radiation therapy

External beam radiation therapy may be used to treat lymphoplasmacytic lymphoma that develops outside of the lymphatic system (called extralymphatic disease), but this is rare.

Stem cell transplant

Some people with lymphoplasmacytic lymphoma may be offered a stem cell transplant. It may be used if the lymphoma comes back (recurs) after treatment or doesn’t respond to other treatments (called refractory disease). Many people with lymphoplasmacytic lymphoma are older or may not be in good health, so a stem cell transplant may not be a good treatment option for them.

Expert review and references

  • American Cancer Society. Non-Hodgkin Lymphoma. 2014:
  • American Society of Clinical Oncology . Lymphoma Non-Hodgkin Overview . 2014 :
  • Freedman AS, Jacobson CA, Mauch P, Aster JC . Non-Hodgkin lymphoma. DeVita VT Jr, Lawrence TS, & Rosenberg SA. Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2015: 103:1552-1583.
  • Medeiros L J . Pathology of non-Hodgkin's and Hodgkin's lymphomas. Wiernik PH, Goldman JM, Dutcher JP, Kyle RA (eds.). Neoplastic Diseases of the Blood. 5th ed. Springer; 2013: 42: 867-918.
  • National Cancer Institute. Adult Non-Hodgkin LymphomaTreatment (PDQ®) Health Professional Version. 2015:

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on, nor do we endorse any service, product, treatment or therapy.

1-888-939-3333 | | © 2024 Canadian Cancer Society